Angioma
Conditions
Keywords
hypnoanalgesia, cutaneous angioma, sclerosis treatment
Brief summary
This study highlights the global management of the various components of outpatient pain by hypnoanalgesia (pain management by hypnosis) in radiopediatrics. Indeed, pain is induced by sclerosis of cutaneous angiomas in interventional radiology. It is managed by MEOPA (an equimolar mixture of oxygen nitrous oxide) or by general anesthesia. For four years, the medical electroradiology technologist of the Mother and Child Hospital (HFME) of the Hospices Civils de Lyon offer patients in addition a pain management by hypnoanalgesia. The investigator propose a multicenter open randomized study comparing two pain management strategies, in children aged 7 to 18 years treated for cutaneous angioma by sclerosis in interventional radiology at the HFME. The two strategies studied are: Hypnoanalgesia and MEOPA (the reference strategy). The main objective is to evaluate the efficacy of hypnoanalgesia compared to the standard of care of pain, which is the use of MEOPA, in the treatment of sclerosis of cutaneous angioma in pediatric interventional radiology.
Interventions
OTHERHypnoanalgesia group
The running of a hypnosis session is protocolized and is based on three times: * The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability. * The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged, * The time of return. It is time that allows the patient to regain his classic state of consciousness.
OTHERMeopa Group
The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure. For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Child requiring a first treatment with sclerosis cutaneous angioma whose location allows treatment in interventional radiology room, * Child from 7 to 18 years old on the day of treatment, * Free and informed consent of the child and his parents (or legal representative), * Patient affiliated to a social security scheme
Exclusion criteria
* Child under tutorship or guardianship, * Child suffering from severe psychotic disorders or under psychotropic drug treatment, * Child who has already had angioma sclerosis in the interventional radiology room. Indeed, the child can remember a previous support and have a priori, positive or negative, on the new support (memory bias), * Child not speaking French, * Deaf child or hearing impaired not allowing easy listening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| assessment of pain score by Visual Analog Scale (EVA) | Day 0 | Comparison of the pain score felt by the child during the procedure (score 0 or 1, absence or presence of pain, on an Analog Visual Scale (EVA)) between the MEOPA group and the hypnoanalgesia group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of side effects | Day 0 | comparaison between groups. |
| gravity of side effects | Day 0 | comparaison between groups. |
| Patient satisfaction assessed by a satisfaction questionary | Day 0 | — |
| Patient anxiety score assessed by anxiety Visual Analog Scale (EVA) | Day 0 | — |
| anxiety assessed by Visual Analog Scale (EVA) | Day 0 | — |
| number of injections performed per site | Day 0 | — |
| MEOPA administration time | Day 0 | — |
| Pain assessed by Visual Analog Scale (EVA) | Day 0 | — |
Countries
France
Contacts
Primary ContactClaire BENOIT-RUBY
Backup ContactAdeline Mansuy
Outcome results
None listed